537034-15-4 Usage
Uses
Used in Pharmaceutical Industry:
N-(2-Aminophenyl)-N'-phenylheptanediamide is used as a histone deacetylase inhibitor for the treatment of Friedrich's ataxia (FRDA). It works by increasing the acetylation of histones H3 and H4 at specific sites (H3K14, H4K5, and H4K12), which results in the reversal of FXN gene silencing and a subsequent increase in FXN mRNA and frataxin expression. N-(2-Aminophenyl)-N'-phenylheptanediamide has shown promising results in primary FRDA lymphocytes and FRDA cell lines, offering a potential therapeutic approach for patients with FRDA.
Used in Research Applications:
In the field of molecular biology and drug discovery, N-(2-Aminophenyl)-N'-phenylheptanediamide serves as a valuable research tool for studying the role of histone acetylation in gene regulation and the development of targeted HDAC inhibitors. Its specificity for the FXN gene makes it an attractive candidate for investigating the epigenetic mechanisms underlying FRDA and other related disorders.
Chemical Properties:
N-(2-Aminophenyl)-N'-phenylheptanediamide is an off-white solid, which indicates its stability and suitability for use in various experimental setups and pharmaceutical formulations.
Biochem/physiol Actions
Cell permeable: yes
Check Digit Verification of cas no
The CAS Registry Mumber 537034-15-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,3,7,0,3 and 4 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 537034-15:
(8*5)+(7*3)+(6*7)+(5*0)+(4*3)+(3*4)+(2*1)+(1*5)=134
134 % 10 = 4
So 537034-15-4 is a valid CAS Registry Number.
537034-15-4Relevant academic research and scientific papers
HISTONE DEACETYLASE INHIBITORS AS THERAPEUTICS FOR NEUROLOGICAL DISEASES
-
Page/Page column 41; 42, (2008/06/13)
The invention provides HDAC inhibitors that may be used as therapeutics for the treatment of a neurodegenerative or neuromuscular condition. The invention provides compounds of formula I. The invention also provides pharmaceutical compositions and articles of manufacture that include these compounds, as well as methods of treating and methods of preventing or delaying the onset of a neurodegenerative or neuromuscular condition.
Structural biasing elements for in-cell histone deacetylase paralog selectivity
Wong, Jason C.,Hong, Roger,Schreiber, Stuart L.
, p. 5586 - 5587 (2007/10/03)
We use the structural dissection of two 1,3-dioxanes with in-cell histone deacetylase (HDAC) paralog selectivity to identify key elements for selective HDAC inhibitors. We demonstrate that o-aminoanilides are inactive toward HDAC6 while apparently inhibit
